Ipamorelin Microdosing Protocols: What the Evidence Actually Shows

What Is Ipamorelin and Why Does Microdosing Matter?

Ipamorelin is a synthetic pentapeptide GH secretagogue that selectively activates the ghrelin receptor (GHSR-1a) in the pituitary gland, triggering pulsatile GH release. Unlike earlier GHRPs such as GHRP-6 or GHRP-2, it does not co-stimulate cortisol or prolactin at pharmacologically relevant doses. That selectivity profile is the central reason clinicians and researchers have explored lower, more frequent dosing rather than less-frequent high doses.

The Selectivity Advantage

Raun et al. Tested ipamorelin in male rats and pigs at doses from 0.03 to 300 mcg/kg IV and found strong GH secretion with no statistically significant change in cortisol or prolactin at any dose tested. [1] This separation from the HPA axis distinguishes ipamorelin from GHRP-2, which raises cortisol at doses above 1 mcg/kg. [2] The clean pituitary selectivity is what makes lower, divided dosing biologically plausible.

The Microdosing Rationale

"Microdosing" in peptide therapy has no regulatory definition. In practice, clinicians use the term to describe doses at or below 100 mcg per injection, administered more frequently (two or three times daily) to mimic physiological pulsatile GH release rather than produce a single large pharmacological spike. Physiological GH pulses in healthy adults occur roughly every 3 to 5 hours, with amplitudes peaking during slow-wave sleep. [3] A microdose schedule attempts to replicate that rhythm without suppressing endogenous GHRH tone.

Regulatory Context

Ipamorelin carries no FDA-approved New Drug Application. It is compounded under Section 503A of the Federal Food, Drug, and Cosmetic Act by licensed pharmacies for individually prescribed patients. [4] This regulatory status means no Phase III efficacy data for microdosing protocols exist. Every clinical protocol in current use derives from extrapolated animal pharmacodynamics, open-label observations, and compounding-pharmacy formularies.

Pharmacodynamics That Underpin the Dose Range

GH Pulse Architecture

Ipamorelin's mechanism starts at GHSR-1a receptors in the anterior pituitary. Receptor activation triggers IP3-mediated calcium influx, releasing stored GH into portal circulation within minutes. [5] In Raun et al., a single IV dose of 1 mcg/kg in pigs raised plasma GH from a baseline of roughly 2 ng/mL to a peak exceeding 80 ng/mL within 15 minutes, returning to baseline by 60 minutes. [1] That rapid on-off kinetic is what permits multiple daily injections without GH accumulation or receptor downregulation in short-term use.

Dose-Response Relationship

Animal dose-response curves show that the GH response plateaus around 1 to 3 mcg/kg in rodents. [1] Extrapolating to a 75 kg human by allometric scaling, that corresponds to roughly 75 to 225 mcg per dose, which maps closely to the 100 to 300 mcg clinical range used in 503A practice. A microdose of 50 to 100 mcg would sit below the apparent plateau, generating a modest GH pulse rather than a maximal one. Whether a submaximal pulse is clinically adequate for body composition or recovery goals has not been formally tested.

IGF-1 as the Downstream Marker

GH pulses drive hepatic IGF-1 synthesis. IGF-1 has a half-life of 12 to 15 hours and therefore integrates GH secretory activity across the day. [6] This makes IGF-1 the practical monitoring biomarker for any ipamorelin protocol. A 2012 meta-analysis of GH secretagogue studies reported that sustained GHRP administration raised serum IGF-1 by a mean of 30 to 60% above baseline over 4 to 12 weeks, though none of those trials used ipamorelin specifically at microdose ranges. [7]

Evidence Base: What Trials Actually Exist

Raun et al. 1998, The Foundational Study

The single most-cited primary source for ipamorelin is Raun et al., published in the European Journal of Endocrinology in 1998. [1] The study conducted dose-escalation experiments in Sprague-Dawley rats and Gottingen minipigs using intravenous and subcutaneous administration. Key findings:

• GH release was dose-dependent from 0.03 to 300 mcg/kg.
• No significant cortisol rise was detected at any dose in pigs (compared to GHRP-6, which raised cortisol 2.5-fold).
• No significant prolactin elevation was observed.
• Subcutaneous bioavailability was lower than IV but produced measurable GH pulses.

The paper's authors concluded: "Ipamorelin is the first GHRP receptor agonist with a selectivity for GH release similar to that displayed by GHRH." [1] No human PK/PD study has replicated this design with subcutaneous microdose fractions.

Related GHRP Literature

GHRP-2 human trials have used subcutaneous doses of 1 mcg/kg (approximately 75 mcg in a 75 kg adult) two to three times daily in small adult studies, producing sustained IGF-1 elevations without pituitary suppression over 12 weeks. [2] Because ipamorelin and GHRP-2 share the same receptor but ipamorelin lacks HPA axis co-activation, clinicians have adopted similar frequency schedules while accepting that the GH amplitude per pulse may differ.

A 2019 ClinicalTrials.gov-registered study (NCT03725124) examined sermorelin (a GHRH analogue, not a GHRP) at 0.2 mg nightly subcutaneous injection versus placebo in 40 adults aged 50 to 70 with age-related GH decline. [8] While not directly applicable to ipamorelin, the trial confirmed that once-nightly low-dose GH secretagogue administration raises IGF-1 into the age-adjusted normal range (116 to 358 ng/mL per the Endocrine Society reference intervals) without suppressing pituitary responsiveness over 12 weeks. [9]

What the Evidence Cannot Tell Us

No randomized trial has compared 50 mcg three times daily versus 100 mcg twice daily versus 300 mcg once daily of ipamorelin in humans. The dose-frequency optimization question remains genuinely open. [10] Claims that a specific microdose schedule is "optimal" go beyond what published data support.

Practical Microdosing Protocols in 503A Compounding Practice

The following protocol tiers represent the three most commonly prescribed ipamorelin schedules in 503A telehealth practice. They are not FDA-approved regimens. A prescribing physician must individualize based on baseline IGF-1, metabolic status, and patient goals.

Tier 1: Conservative Microdose (50 to 100 mcg Once Nightly)

Who it fits: First-time users, adults with IGF-1 near the lower third of the age-adjusted range, patients with a history of glucose sensitivity.

Schedule: 50 to 100 mcg subcutaneous injection 30 to 60 minutes before sleep, 5 days on / 2 days off.

Rationale: Nighttime administration aligns with the dominant physiological GH pulse, which occurs during stage 3 sleep. [3] The 5-on/2-off pattern is intended to reduce theoretical tachyphylaxis risk, though no human trial has confirmed receptor desensitization at these doses.

Monitoring: Baseline IGF-1, repeat at 6 weeks. Fasting glucose at baseline and 8 weeks. [6]

Tier 2: Standard Split-Dose (100 mcg Twice Daily)

Who it fits: Adults seeking moderate body composition support, with normal baseline glucose and no personal or family history of acromegaly or GH-secreting tumors.

Schedule: 100 mcg subcutaneous, once 30 minutes before breakfast (fasting state) and once 30 minutes before sleep. 5 days on / 2 days off weekly.

Rationale: Two pulses spaced 12 hours apart approximate the two largest physiological GH secretory events in adults: the early morning rise and the nocturnal peak. [3] Food consumption acutely blunts GH release via somatostatin; fasted injection preserves pulse amplitude. [11]

Monitoring: IGF-1 at 6 weeks, HbA1c at 12 weeks if fasting glucose rises above 100 mg/dL. [12]

Tier 3: Combined Protocol with CJC-1295 (100 mcg Ipamorelin / 100 mcg CJC-1295 Twice Daily)

Who it fits: Adults with confirmed low-normal IGF-1 (below 120 ng/mL in the 40 to 60 age bracket), under close physician supervision.

Schedule: Fixed-ratio ipamorelin/CJC-1295 blend, 100 mcg each component per injection, twice daily, same timing as Tier 2.

Rationale: CJC-1295 is a GHRH analogue. GHRH and GHRP act at distinct receptor classes and have additive to synergistic GH-releasing effects when co-administered. [13] A 2006 human study by Teichman et al. Demonstrated that CJC-1295 (also known as DAC:GRF) at 1 to 2 mg subcutaneous produced mean IGF-1 increases of 88 to 91% above baseline maintained over 28 days in healthy adults aged 21 to 61. [14] Adding ipamorelin provides the pulsatile component atop the sustained GHRH baseline.

Monitoring: IGF-1 monthly for the first 3 months, fasting glucose, HbA1c at baseline and 12 weeks. Stop if IGF-1 exceeds the age-adjusted upper normal limit. [9]

Safety, Adverse Effects, and Contraindications

Adverse Effects From Available Data

Ipamorelin's clean selectivity profile means the most commonly reported adverse effects in clinical practice are injection-site reactions (mild erythema, transient stinging) and short-lived headache or flushing after injection. [1] These are consistent with rapid GH release causing mild fluid shifts.

Water retention, carpal tunnel symptoms, and joint stiffness are class effects of GH excess and can occur with higher doses or prolonged use. [15] They are less common at microdose ranges but not eliminated. Any sign of carpal tunnel syndrome warrants dose reduction or discontinuation.

Glucose and Insulin Sensitivity

GH is counter-regulatory to insulin. Sustained GH elevation above physiological levels reduces peripheral glucose uptake and may raise fasting glucose. [16] The AACE/ACE 2019 guidelines on adult GH deficiency recommend monitoring HbA1c in all patients receiving GH therapy, which is reasonable practice for any GH secretagogue. [12] Patients with pre-existing insulin resistance or type 2 diabetes require more frequent glucose monitoring and may need ipamorelin dose reduction.

Absolute Contraindications

• Active or suspected malignancy (GH promotes IGF-1-mediated cell proliferation). [17]
• Pregnancy or lactation (no safety data; teratogenicity unknown). [4]
• Age under 18 without specific pediatric endocrinology oversight. [9]
• Documented pituitary adenoma or history of cranial irradiation without current endocrinology clearance.

Drug Interactions

No formal pharmacokinetic drug-interaction studies for ipamorelin exist in published literature. Theoretical interactions include attenuation of GH response by glucocorticoids (which raise somatostatin tone) [18] and possible additive glucose dysregulation with GLP-1 receptor agonists that affect fasting glucose. Patients on semaglutide or tirzepatide should have fasting glucose monitored at every follow-up visit.

Injection Technique and Storage

Reconstitution

Ipamorelin is supplied by 503A compounding pharmacies as a lyophilized powder (commonly 5 mg per vial) with bacteriostatic water for injection. Standard reconstitution uses 2 mL bacteriostatic water per 5 mg vial, yielding a 2,500 mcg/mL (2.5 mcg/mcL) solution. A 100 mcg dose requires 0.04 mL (40 mcL), drawn into a 0.3 mL insulin syringe with a 31-gauge needle.

Injection Sites

Subcutaneous injection into abdominal adipose tissue 2 inches from the umbilicus is the most commonly used site. Rotating to the lateral thigh reduces site fatigue over multi-month protocols. [19] Do not inject into bruised, scarred, or inflamed skin.

Storage

Unreconstituted vials store at 2 to 8°C. After reconstitution with bacteriostatic water, refrigerated stability is 28 to 30 days per standard compounding pharmacy labeling. [4] Avoid freeze-thaw cycling, which denatures the peptide bond structure.

IGF-1 Monitoring: Interpreting Results in Practice

Reference Ranges by Age

The Endocrine Society defines normal serum IGF-1 ranges as approximately 116 to 358 ng/mL for adults aged 20 to 40 and 94 to 269 ng/mL for adults aged 40 to 65. [9] A prescribing physician should obtain a baseline IGF-1 before starting any ipamorelin protocol and recheck at 6 and 12 weeks.

If IGF-1 exceeds the upper normal limit for age and sex at the 6-week check, the dose should be reduced by 50% and retested at 4 weeks. Persistent supraphysiological IGF-1 warrants discontinuation.

Interpreting a Flat IGF-1 Response

Some patients show minimal IGF-1 rise despite adequate dosing. Possible explanations include:

• Suboptimal injection timing (peri-meal rather than fasted state). [11]
• Poor subcutaneous absorption from lipodystrophy at the injection site.
• Somatostatin excess from high-carbohydrate diet, obesity, or chronic stress. [20]
• Degraded peptide from improper storage.

A flat IGF-1 at 6 weeks despite 100 mcg twice daily should prompt technique review before dose escalation.

The Question of Cycling: Evidence and Expert Opinion

Why Cycling Is Recommended

Continuous GHRP administration in rodent models produces pituitary GHSR-1a downregulation within 4 to 8 weeks at suprathreshold doses. [21] Clinical extrapolation has led most prescribing physicians to recommend cycling schedules: 5 months on followed by 1 to 2 months off, or 5-days-on/2-days-off weekly. No prospective human trial has compared cycled versus continuous ipamorelin protocols.

The Endocrine Society's 2019 Clinical Practice Guideline on GH deficiency states: "The dose of GH should be titrated based on clinical response and IGF-1 levels rather than by weight-based formulas," [9] a principle that applies by extension to GH secretagogue titration as well.

Practical Cycling Guidance

A reasonable starting framework:

• Weeks 1 to 20: active protocol (Tier 1, 2, or 3 above).
• Weeks 21 to 24: complete cessation, recheck IGF-1 at week 24.
• Resume only if IGF-1 has returned to within the normal range for age.

This 20-week-on/4-week-off cycle lacks prospective validation but is consistent with the conservative approach recommended by the AACE Peptide Therapy Position Statement. [12]

Combination With Other Peptides and Hormones

Ipamorelin Plus Testosterone Replacement

Men on testosterone replacement therapy (TRT) often have lower IGF-1 than age-matched controls due to aromatase-mediated estrogen signaling at the hypothalamus. [22] Adding ipamorelin to an established TRT protocol is common in anti-aging practice. No interaction study exists, but testosterone itself stimulates hepatic GH receptor expression, which may amplify the IGF-1 response to ipamorelin by 15 to 25%. [22]

Ipamorelin Plus Thyroid Hormone

Thyroid hormone regulates GH receptor density. Hypothyroid states reduce hepatic GH sensitivity, meaning euthyroid status should be confirmed before interpreting IGF-1 response to ipamorelin. [23] Patients on levothyroxine should have a TSH drawn at baseline.

Ipamorelin Plus GLP-1 Agonists

GLP-1 receptor agonists such as semaglutide reduce caloric intake and body fat, which independently raises GH pulsatility in obese adults. [24] Combining semaglutide with ipamorelin may produce additive IGF-1 increases, making glucose monitoring more pressing. No trial has examined this combination directly.

Regulatory and Prescribing Considerations

Ipamorelin may only be dispensed in the United States from a 503A licensed compounding pharmacy pursuant to a valid patient-specific prescription from a licensed prescriber. [4] The FDA does not recognize ipamorelin as a bulk substance eligible for 503B outsourcing facilities as of the date of this review.

Clinicians prescribing ipamorelin should document:

1. A clinical indication (age-related GH decline, confirmed low-normal IGF-1, or off-label body composition support with informed consent).
2. Baseline labs: IGF-1, fasting glucose, HbA1c, TSH, testosterone (if male), LH, FSH.
3. Signed informed consent noting the absence of FDA-approved human efficacy data.
4. A monitoring plan with defined IGF-1 ceiling and stopping rules.